These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 7952993

  • 21. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
    Dixon L, Thaker G, Conley R, Ross D, Cascella N, Tamminga C.
    Schizophr Res; 1993 Oct; 10(3):267-71. PubMed ID: 8260445
    [Abstract] [Full Text] [Related]

  • 22. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia.
    Lang AE.
    Mov Disord; 1994 Mar; 9(2):188-92. PubMed ID: 8196681
    [Abstract] [Full Text] [Related]

  • 23. Akathisia in adults with mental retardation: development of the Akathisia Ratings of Movement Scale (ARMS).
    Bodfish JW, Newell KM, Sprague RL, Harper VN, Lewis MH.
    Am J Ment Retard; 1997 Jan; 101(4):413-23. PubMed ID: 9017087
    [Abstract] [Full Text] [Related]

  • 24. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
    Modestin J, Wehrli MV, Stephan PL, Agarwalla P.
    Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
    [Abstract] [Full Text] [Related]

  • 25. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
    Goff DC, Henderson DC, Amico E.
    Am J Psychiatry; 1992 Sep; 149(9):1189-94. PubMed ID: 1503131
    [Abstract] [Full Text] [Related]

  • 26. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
    McEvoy JP, Hogarty GE, Steingard S.
    Arch Gen Psychiatry; 1991 Aug; 48(8):739-45. PubMed ID: 1883257
    [Abstract] [Full Text] [Related]

  • 27. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [Abstract] [Full Text] [Related]

  • 28. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB.
    J Clin Psychiatry; 1997 Apr; 58 Suppl 10():45-9. PubMed ID: 9265916
    [Abstract] [Full Text] [Related]

  • 29. The prevalence of akathisia in patients receiving stable doses of clozapine.
    Chengappa KN, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J.
    J Clin Psychiatry; 1994 Apr; 55(4):142-5. PubMed ID: 7915271
    [Abstract] [Full Text] [Related]

  • 30. Clinical characteristics and predisposing factors in acute drug-induced akathisia.
    Sachdev P, Kruk J.
    Arch Gen Psychiatry; 1994 Dec; 51(12):963-74. PubMed ID: 7979885
    [Abstract] [Full Text] [Related]

  • 31. Akathisia and exacerbation of psychopathology: a preliminary report.
    Duncan EJ, Adler LA, Stephanides M, Sanfilipo M, Angrist B.
    Clin Neuropharmacol; 2000 Dec; 23(3):169-73. PubMed ID: 10895402
    [Abstract] [Full Text] [Related]

  • 32. [Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study].
    Romain JL, Dermain P, Greslé P, Grignon S, Moisan P, Nore D, Pech G, Benyaya J, Perret I.
    Encephale; 1996 Dec; 22(4):280-6. PubMed ID: 9035983
    [Abstract] [Full Text] [Related]

  • 33. Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases.
    Nisijima K, Ishiguro T.
    J ECT; 1999 Jun; 15(2):158-63. PubMed ID: 10378156
    [Abstract] [Full Text] [Related]

  • 34. [Rapid and megadose neuroleptic therapy. Critical review].
    de Girolamo G.
    Minerva Psichiatr; 1985 Jun; 26(4):323-6. PubMed ID: 2869395
    [No Abstract] [Full Text] [Related]

  • 35. Is neuroleptic dysphoria a healthy response?
    Weiden PJ, Mann JJ, Dixon L, Haas G, DeChillo N, Frances AJ.
    Compr Psychiatry; 1989 Jun; 30(6):546-52. PubMed ID: 2573481
    [Abstract] [Full Text] [Related]

  • 36. Severe akathisia causing neuroleptic failure: an indication for lithium therapy in schizophrenia?
    Shalev A, Hermesh H, Munitz H.
    Acta Psychiatr Scand; 1987 Dec; 76(6):715-8. PubMed ID: 2894745
    [Abstract] [Full Text] [Related]

  • 37. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
    Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Martinez-Garcia O, Neergaard KD, Tabares-Seisdedos R, Crespo-Facorro B.
    Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
    [Abstract] [Full Text] [Related]

  • 38. [Neuroleptic-induced dysphoric response in non-schizophrenic patients].
    Berardi D, Zanfini R, Alessi S, Giannelli A, Ferrari G.
    Minerva Psichiatr; 1993 Jun; 34(2):125-33. PubMed ID: 8105358
    [Abstract] [Full Text] [Related]

  • 39. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB.
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
    Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, McQuade R, Tran QV, Pikalov A, Assunção-Talbott S.
    J Psychopharmacol; 2010 Jul; 24(7):1019-29. PubMed ID: 20008446
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.